

1 **Title:** Psoriasis and Comorbid Diseases Part II. Implications for Management

2

3 **Authors:** Junko Takeshita, MD, PhD, MSCE^{1,2}; Sungat Grewal, BS¹; Sinéad M. Langan, MB,
4 BCh, BAO, MRCP, MSc, PhD³; Nehal N. Mehta, MD, MSCE⁴; Alexis Ogdie, MD, MSCE^{2,5};
5 Abby S. Van Voorhees, MD⁶; Joel M. Gelfand, MD, MSCE^{1,2}.

6

7 **Author Affiliations:** Departments of Dermatology¹, Epidemiology and Biostatistics, Center for
8 Clinical Epidemiology and Biostatistics², and Division of Rheumatology⁵, University of
9 Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; London School of Hygiene
10 and Tropical Medicine and St. John's Institute of Dermatology, London, United Kingdom³;
11 National Heart, Lung and Blood Institute, Bethesda, MD, USA⁴; Department of Dermatology,
12 Eastern Virginia Medical School, Norfolk, VA, USA⁶.

13

14 **Corresponding Author:** Junko Takeshita, MD PhD MSCE, Department of Dermatology,
15 University of Pennsylvania, 3400 Spruce St., 1104 Dulles, Philadelphia, PA 19104. Email:
16 Junko.Takeshita@uphs.upenn.edu. Phone: 215-349-5551. Fax: 215-615-3127.

17

18 **Funding/Support:** This work was supported in part by the National Institute of Arthritis and
19 Musculoskeletal and Skin Diseases K24AR064310 (Gelfand), T32AR007465-32 (Grewal),
20 K23AR063764 (Ogdie), and K23AR068433 (Takeshita) grants, Dermatology Foundation Career
21 Development Award (Takeshita), the Intramural Research Program at the National Institutes of
22 Health, ZIAHL006193-02 (Mehta), and National Institute for Health Research Clinician Scientist

23 Fellowship, NIHR/CS/010/014 (Langan). The findings and conclusions in this report are those of
24 the authors and do not necessarily represent the views of the U.K. Department of Health.

25

26 **Conflict of Interest Disclosures:** Dr. Takeshita receives a research grant (to the Trustees of the
27 University of Pennsylvania) from Pfizer and payment for continuing medical education work
28 related to psoriasis. Dr. Mehta is a full time U.S. Government employee. Dr. Ogdie receives
29 research grants from AbbVie (to the Group for Research and Assessment of Psoriasis and
30 Psoriatic Arthritis [GRAPPA]), Celgene (to GRAPPA), and Pfizer Inc. (to the Trustees of the
31 University of Pennsylvania and GRAPPA), and has served as a consultant for Novartis, receiving
32 honoraria. Dr. Van Voorhees has served as a consultant for AbbVie, Amgen, Aqua, Astra
33 Zeneca, Celgene, Corrona, Dermira, Janssen, Leo, Novartis, and Pfizer, receiving honoraria;
34 received a research grant from AbbVie; and has other relationship with Merck. Dr. Gelfand has
35 served as a consultant for AbbVie, AstraZeneca, Celgene Corp, Coherus, Eli Lilly, Janssen
36 Biologics (formerly Centocor), Sanofi, Merck, Novartis Corp, Endo, and Pfizer Inc., receiving
37 honoraria; and receives research grants (to the Trustees of the University of Pennsylvania) from
38 AbbVie, Amgen, Eli Lilly, Janssen, Novartis Corp, Regeneron, and Pfizer Inc.; and received
39 payment for continuing medical education work related to psoriasis. Dr. Gelfand is a co-patent
40 holder of resiquimod for treatment of cutaneous T cell lymphoma.

41

42 **Abstract word count:** 94

43

44 **Manuscript word count:** 3473

45

46 **Reference count:** 99

47

48 **Table count:** 4

49

50 **Figure count:** 0